Denali Therapeutics Inc — Financial Statements (NASDAQ:DNLI) | MetaTrader

Open full chart

News

Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up

FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript

Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval

Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript

Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?

Stifel sees rare disease stocks gaining after FDA official exit

Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Jefferies reiterates Denali stock Buy rating on gene therapy outlook

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus